Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alphabet

Microsoft

Starbucks

AT&T

Taking a look at major names, these five stand out as stocks to buy on the dip:
Alphabet (NASDAQ:GOOG,NASDAQ:GOOGL)
AT&T (NYSE:T)
Johnson & Johnson (NYSE:JNJ)
Microsoft (NASDAQ:MSFT)
Starbucks (NASDAQ:SBUX)
Granted, FUD (fear, uncertainty, and doubt) remain, even as markets trend higher. But, the relative strengths of these 5 names could make them buys on a pullback.

The Best 5 Stocks to Buy on the Next Dip

Brookfield Renewable Partners

Dollar General

Every stock has some level of risk. But these have less than most.

3 Great Stocks for Low-Risk Investors: BEP, DG & JNJ

Johnson & Johnson is a great pick for dividend investors.

Here’s How to Find the Best Dividend Stocks

NEW BRUNSWICK, N.J., May 28, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 10. Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will represent the...

Johnson & Johnson to Participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference

The healthcare giant's done well over the years, but will that continue amid its legal problems?

Is Johnson and Johnson Stock a Buy?

Atlanta Braves Holdings Inc

Carnival

Moderna

Norwegian Cruise Line

Royal Caribbean Cruises

How to profit off of the recent vaccine craze.

How I Pick Approved Needles in a Vaccine Haystack

American States Water

Colgate-Palmolive

Dover

Lowe's

The "forever" part means investors have to think about the longevity of payout growth as well as reliable payments.

5 Dividend Kings to Buy and Hold Forever

Apple

Coca-Cola

McDonald's

NIKE

Visa

Several billionaire investors believe the markets are overvalued. Here are seven Dow Jones stocks to buy in this uncertain environment.

7 Dow Jones Stocks to Buy With Fortress-Like Balance Sheets

Sales have dropped due to cancer concerns.

Johnson & Johnson Plans to Stop Selling Talc-Based Baby Powder

General Dynamics

Exxon Mobil

The 2020 S&P 500 Dividend Aristocrats list includes 66 companies that have increased dividends (not just remained the same) for 25 years straight.

5 Dividend Aristocrat Stocks to Buy That Could Weather Another Brutal Sell-Off

J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

J&J to Stop Sale of Talc-Based Baby Powder in North America

Johnson & Johnson is to stop selling its talc-based Johnson's Baby Powder in the US and Canada, saying demand had dropped because of "misinformation" about the product's safety.

Johnson & Johnson to stop selling baby powder in US and Canada

Johnson & Johnson on Tuesday announced it would stop selling its talc Baby Powder in the United States and Canada, saying demand had dropped in the wake of what it called "misinformation" about the product’s safety amid a barrage of legal challenges.     J&J faces more than 19,000 lawsuits from consumers and their survivors claiming its talc products caused cancer due to contamination with asbestos, a known carcinogen.

Johnson & Johnson to stop selling talc baby powder in U.S. and Canada

FAIRLESS HILLS, Pa. — Johnson & Johnson is ending sales of its iconic talc-based Johnson’s Baby Powder in the U.S.

Johnson & Johnson stops selling talc-based baby powder in North America

Johnson & Johnson (NYSE: JNJ) on Tuesday announced it is discontinuing its talc-based baby powder line in the United States and Canada.

Johnson & Johnson Pulls Talc-Based Baby Powder From US, Canada As Cancer Claims Kill Demand

HOUSTON, May 19, 2020 /PRNewswire/ -- Mark Lanier, the trial lawyer who earned the largest jury verdict to date on behalf of consumers who have developed cancer from talc-based cosmetics, welcomed an announcement by Johnson & Johnson (NYSE: JNJ) that it would cease manufacturing products...

Attorney Mark Lanier 'Gratified but Not Yet Satisfied' by Johnson & Johnson Decision to Discontinue Talc-Based Baby Powder

The phamaceutical giant continues to defend the product’s safety, but says demand for the talc-based powder is declining

Johnson & Johnson (JNJ) to stop selling baby powder in US and Canada

Thousands of lawsuits claim the product causes cancer, though the company denies this.

Johnson & Johnson  Discontinues Talc-Based Baby Powder In US And Canada

Dow Jones stock Johnson & Johnson said Tuesday it's discontinuing its baby powder in the U.S. and Canada as demand dives amid lawsuits claiming the talc-based products cause cancer.

Johnson & Johnson Pulls Baby Powder From U.S., Canada As Demand Plummets

Johnson & Johnson Inc. JNJ, -0.99% said late Tuesday it will stop selling talc-based baby powder in North America following a flurry of lawsuits alleging the product causes cancer.

J&J pulls sale of talc-based baby powder in North America

Johnson & Johnson on Tuesday announced that it would stop selling its talc-based Johnson’s Baby Powder in the United States and Canada, saying it was part of a broad reassessment of its consumer product portfolio prompted by the coronavirus pandemic.

Johnson & Johnson to stop selling talc-based Johnson's Baby Powder in U.S., Canada

J&J says it is discontinuing its talc-based baby powder in the United States and Canada as demand fell in light of mounting lawsuits that said it caused cancer.

Johnson & Johnson discontinues talc-based baby powder in US and Canada

A double-sided antibody with blockbuster potential shrank tumors for relapsed multiple myeloma patients who have run out of treatment options.

Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results

Emergent BioSolutions

Which of these COVID-19 partners is the better pick? Here's how J&J and Emergent stack up against each other.

Better Coronavirus Stock: Johnson & Johnson or Emergent BioSolutions?

Prem Watsa (Trades, Portfolio)'s Fairfax Financial Holdings sold shares of the following stocks during the first quarter of 2020.

News for Johnson & Johnson Stock (JNJ)